An interventional study of Propofol and Ciprofol in Anesthesia; Adverse Effect and Biliary Tract Diseases, sponsored by RenJi Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-31.
Sponsored by RenJi Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Intravenous anesthesia has been widely used in endoscopic retrograde cholangiopancreatography (ERCP). In the past decade, many practices have been carried out under the propofol-based monitored anesthesia care without endotracheal intubation in patients undergoing ERCP.
Ciprofol is a newly developed intravenous anesthetic with a potency 4-5 times than that of propofol. Ciprofol seems a promising anesthetic agent for intravenous anesthesia but the evidence supported its application in ERCP is still limited.
This is a prospective, randomized, double-blind trial comparing the incidence of hypoxia in the propofol versus ciprofol intravenous Anesthesia. A total 136 patients will be recruited and randomly assigned to either the propofol or the ciprofol group. The primary outcome is the proportion of patients experiencing hypoxia. The secondary outcomes include: the incidence of hypotension in perioperative period; the incidence of conversion from intravenous anesthesia to general anesthesia; sedation-related procedure interruption; carbon dioxide( CO2) accumulation during operation; Patients' satisfaction with anesthesia and postoperative recovery / VAS score / incidence of nausea and vomiting; the incidence of intraoperative and postoperative adverse events, such as adverse excretion, severe hypoxemia, severe circulatory dysfunction; length of stay and mortality within 30 days after operation.
59 studies on the registry are indexed under Biliary Tract Diseases; 12 are open to participants now.
This study's planned enrollment of 136 is above the median of 84 across 37 interventional studies indexed under Biliary Tract Diseases.
Browse Biliary Tract Diseases studies →RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients in Propofol group receive sufentanil+ propofol
Drug: Propofol
patients in Ciprofol group receive sufentanil+ ciprofol
Drug: Ciprofol
patients in Propofol group receive sufentanil(0.1ug/kg)+ propofol (1.5-2mg/kg) for anesthesia induction, and continuous infusion of propofol 5mg/kg/h for anesthesia maintain.
Also known as: Fresenius Kabi,China
patients in Ciprofol group receive sufentanil(0.1ug/kg)+ ciprofol(0.4-0.5mg/kg) for anesthesia induction, and continuous infusion of ciprofol 0.8mg/kg/h for anesthesia maintain.
Also known as: Haisike,China
the incidence of hypoxia
the definition of hypoxemia: any event of SpO2 (oxygen saturation measured by pulse oximetry) \< 90%
Time frame: from the induction of anesthesia to the patient leaving the postanesthesia care unit,about an average of 1.5 hours
the incidence of hypercapnia
arterial carbon dioxide partial pressure(PaCO2)\>50mmHg
Time frame: 5 minutes each time(base line, 10 minutes after beginning of surgery, completion of surgery, 10 minutes after awakening)
the incidence of hypotension
invasive systolic pressure\<90mmHg
Time frame: from the induction of anesthesia to the patient leaving the postanesthesia care unit,about an average of 1.5 hours
sedation-related procedure interruption
the incidence of interruption of procedure due to intolerance or severe adverse events
Time frame: from the induction of anesthesia to completion of ERCP, about 30 minutes
conversion from intravenous anesthesia to general anesthesia
the incidence of conversion from intravenous anesthesia to general anesthesia due to intolerance or severe adverse events
Time frame: from the induction of anesthesia to completion of ERCP, about 30 minutes
patient satisfaction score
Patients' satisfaction score is measured by patient recovery satisfaction score, from -33 the worst to 33 the best.
Time frame: 5 minutes
visual analog scale (VAS) scores
perioperative pain is measured by visual analog scale (VAS) scores,from painless score 0 to the imagined most severe pain score 10
Time frame: 30 seconds
length of stay
length of stay in hospital
Time frame: 2-7days
the incidence of postoperative adverse bile excretion
patients with symptoms or signs of postoperative adverse bile excretion
Time frame: 30 days after operation
the incidence of severe postoperative hypoxia
patients with symptoms or signs of severe postoperative hypoxia
Time frame: 30 days after operation
the incidence of severe postoperative circulatory disfunction
patients with symptoms or signs of severe postoperative circulatory disfunction
Time frame: 30 days after operation
the incidence of mortality within 30 days after operation
mortality within 30 days after operation
Time frame: 30 days after operation
Plan to share: No
Start is estimated for Jun 2024; primary completion for Dec 2024, 6 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ciprofol